Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06564142 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
A Phase 3 study of Immunoglobulin A Nephropathy, sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex.
- Active
- Registry status
- Phase 3
- Development phase
- 605
- Enrollment target
- 20
- Study locations
NCT06564142: Active Phase 3 study of Immunoglobulin A Nephropathy, sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex.
NCT06564142 is a Phase 3 study of Immunoglobulin A Nephropathy that is active but no longer recruiting, run by Alpine Immune Sciences Inc, A Subsidiary of Vertex. The registered enrollment target is 605 participants, above the 258-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (134% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06564142, a Phase 3 study of Immunoglobulin A Nephropathy, is active but no longer recruiting, sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 605 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.
Conditions Studied
Interventions
- DRUG Povetacicept
- DRUG Placebo (matched to Povetacicept)
Study Locations (20)
California
- West Coast Kidney - Fremont
- The Medical Research Group, Inc. (FRENOVA) - Fresno
- CARE Institute - Carabello Kidney - Los Angeles
- Providence Medical Foundation - Orange - Orange
- National Nephrology Alliance Research - Riverside
- UC Davis Health - Sacramento
- Zuckerberg San Francisco General Hospital and Trauma Center - San Francisco
- University of California San Francisco (UCSF) - San Francisco
Florida
- South Florida Nephrology Group PA, Research Div. - Coral Springs
- Dolphin Medical Research - Doral
- Nephrology Associates of Central Florida - Hollywood
- Tectum Medical Research, LLC - Hollywood
- South Florida Research Institute - Lauderdale Lakes
- Florida Kidney Physicians - Melbourne - Melbourne
Arizona
- Arizona Kidney Disease and Hypertension Center - Thomas Office - Phoenix
- Arizona Kidney Disease and Hypertension Center - Tuscon - Tucson
Colorado
- Western Nephrology - Arvada
- Colorado Kidney Care - Denver
Alabama
- Apogee Clinical Research, LLC - Huntsville
Delaware
- Nephrology Associates Delaware Kidney (FRENOVA) - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 605 participants |
| Start Date | 2024-08-30 |
| Est. Completion | 2028-01-30 |
| Phase | Phase 3 |
What the registry record for NCT06564142 still lists
NCT06564142 is an interventional study that assigns participants to a tested intervention. The registered 605 participants enrollment target is mid-sized for trials with a published cap, above the 258-participant average among 13 other Immunoglobulin A Nephropathy trials with a reported enrollment target (134% higher).
The record links to 1 condition, with Immunoglobulin A Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Povetacicept is the first listed.
NCT06564142 names 20 study sites across 6 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06564142 about?
NCT06564142 is a clinical study titled "Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)". The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.
What is the current status of trial NCT06564142?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 605 participants. The study started on 2024-08-30. Estimated completion is 2028-01-30.
What conditions does trial NCT06564142 study?
This clinical trial studies the following conditions: Immunoglobulin A Nephropathy.
What interventions are being tested in trial NCT06564142?
The interventions under investigation include: Povetacicept (DRUG), Placebo (matched to Povetacicept) (DRUG).
Who is sponsoring clinical trial NCT06564142?
This trial is sponsored by Alpine Immune Sciences Inc, A Subsidiary of Vertex, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06564142 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immunoglobulin A Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06564142's enrollment target sits among peer trials
605 1st of 13 higher than 13 of 13 other Immunoglobulin A Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Immunoglobulin A Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Ravulizumab in Pediatric Participants With Primary IgAN
RECRUITING · Phase 3
-
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
RECRUITING · Phase 3
-
Atrasentan in Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Zigakibart in Adults With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
- NCT05238922 · 604 participants · Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- NCT06040541 · 604 participants · Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI